Shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) have earned an average rating of “Hold” from the eleven research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $62.63.

IONS has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $58.00 price objective on the stock in a research report on Wednesday, January 2nd. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 28th. BMO Capital Markets upped their price objective on shares of Ionis Pharmaceuticals from $70.00 to $82.00 and gave the stock an “outperform” rating in a research report on Thursday, February 28th. Piper Jaffray Companies upped their price objective on shares of Ionis Pharmaceuticals to $60.00 and gave the stock a “neutral” rating in a research report on Thursday, February 28th. Finally, Morgan Stanley set a $71.00 price objective on shares of Ionis Pharmaceuticals and gave the stock a “hold” rating in a research report on Friday, March 1st.

Shares of IONS stock traded down $10.61 during trading on Wednesday, hitting $72.67. The company had a trading volume of 3,767,681 shares, compared to its average volume of 1,066,805. The company has a current ratio of 7.88, a quick ratio of 7.85 and a debt-to-equity ratio of 0.53. The stock has a market cap of $11.53 billion, a price-to-earnings ratio of 24.55, a price-to-earnings-growth ratio of 179.74 and a beta of 2.42. Ionis Pharmaceuticals has a 52 week low of $39.07 and a 52 week high of $86.58.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Wednesday, February 27th. The company reported $2.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.04) by $2.46. The company had revenue of $192.00 million for the quarter, compared to analysts’ expectations of $159.59 million. Ionis Pharmaceuticals had a net margin of 45.64% and a return on equity of 41.89%. Ionis Pharmaceuticals’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.03) earnings per share. As a group, sell-side analysts forecast that Ionis Pharmaceuticals will post 0.03 EPS for the current fiscal year.

In other Ionis Pharmaceuticals news, SVP C Frank Bennett sold 9,013 shares of the company’s stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $58.29, for a total value of $525,367.77. Following the completion of the sale, the senior vice president now owns 33,541 shares of the company’s stock, valued at $1,955,104.89. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Patrick R. O’neil sold 19,600 shares of the company’s stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $59.25, for a total value of $1,161,300.00. Following the completion of the sale, the senior vice president now directly owns 23,673 shares of the company’s stock, valued at approximately $1,402,625.25. The disclosure for this sale can be found here. In the last ninety days, insiders sold 339,205 shares of company stock valued at $24,034,607. 2.44% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of IONS. Norges Bank purchased a new stake in Ionis Pharmaceuticals in the fourth quarter worth approximately $54,463,000. American Century Companies Inc. boosted its stake in shares of Ionis Pharmaceuticals by 34.8% during the fourth quarter. American Century Companies Inc. now owns 1,604,974 shares of the company’s stock valued at $86,765,000 after purchasing an additional 414,255 shares during the period. BlackRock Inc. boosted its stake in shares of Ionis Pharmaceuticals by 5.8% during the third quarter. BlackRock Inc. now owns 7,463,257 shares of the company’s stock valued at $384,955,000 after purchasing an additional 408,678 shares during the period. Two Sigma Advisers LP boosted its stake in shares of Ionis Pharmaceuticals by 96.9% during the fourth quarter. Two Sigma Advisers LP now owns 606,911 shares of the company’s stock valued at $32,810,000 after purchasing an additional 298,700 shares during the period. Finally, D. E. Shaw & Co. Inc. boosted its stake in shares of Ionis Pharmaceuticals by 252.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 410,699 shares of the company’s stock valued at $22,202,000 after purchasing an additional 294,184 shares during the period. 85.05% of the stock is owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Featured Story: Net Margin – Understanding the Different Kinds of Profit

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.